Human Anti-HIV-1 gp120 Recombinant Antibody (clone CH38) (CAT#: MRO-3131CQ)

Figure 1 The majority of HIV-1 Env antibodies do not block Galcer binding of a T/F virus Env, but a few RV135/144 vaccinee-derived antibodies do partially block Galcer binding.

The ability of blocking Galcer binding of 1086C gp140 by RV135/144 vaccinee antibodies specific to the gp120 V3 region (CH23), gp120 C1 region (CH29 to CH94), and specific to the gp120 V1V2 region (CH58 and CH59). The percent blocking dataand the error bars shown are from two separate measurements.

Dennison, S. M., Anasti, K. M., Jaeger, F. H., Stewart, S. M., Pollara, J., Liu, P., ... & Ferrari, G. (2014). Vaccine-induced HIV-1 envelope gp120 constant region 1-specific antibodies expose a CD4-inducible epitope and block the interaction of HIV-1 gp140 with galactosylceramide. Journal of virology, 88(16), 9406-9417.

Figure 2 CH38 binds the surface of HIV-1-infected cells and mediates ADCC.

Activated primary human CD4+T cells were mock infected with HIV-1 1086.c infectious molecular clone (IMC) for 3 days. The cells were incubated with no MAbs (filled gray), negative-control MAb Palivizumab (black lines), or CH38 (green lines) for 2h at 37°C to allow binding. Both Palivizumab and CH38 were used at 1 μg/ml. The cells were stained with a viability dyeand anti-p24 to identify viable infected cells, and MAb binding was detected by secondary staining with FITC-conjugated goat anti-human IgG. Representative histograms are shown.

Dennison, S. M., Anasti, K. M., Jaeger, F. H., Stewart, S. M., Pollara, J., Liu, P., ... & Ferrari, G. (2014). Vaccine-induced HIV-1 envelope gp120 constant region 1-specific antibodies expose a CD4-inducible epitope and block the interaction of HIV-1 gp140 with galactosylceramide. Journal of virology, 88(16), 9406-9417.

Figure 3 Peak ADCC activity of CH38 in the 6-h luciferase cell killing assay with HIV-1 1086.c IMC-infected CEM.NKRCCR5 target cells and NK cells isolated from a healthy donor.

Palivizumab and plasma from an HIV-1-seronegative (HIV-1 SN) donor were included as negative controls, and plasma from an HIV-1-seropositive donor (HIV-1 SP) was included as a positive control.

Dennison, S. M., Anasti, K. M., Jaeger, F. H., Stewart, S. M., Pollara, J., Liu, P., ... & Ferrari, G. (2014). Vaccine-induced HIV-1 envelope gp120 constant region 1-specific antibodies expose a CD4-inducible epitope and block the interaction of HIV-1 gp140 with galactosylceramide. Journal of virology, 88(16), 9406-9417.

Figure 4 Selected monomeric IgA2 gp120 antibodies block Galcer binding of aT/F virus Env gp140.

The percent blocking of Galcer liposome binding of1086.C gp140 (50 μg/ml) is shown as a function of concentration of mono-meric IgA 2 antibodies CH38 (diamonds), 7B2 (inverted triangles), and hu-man plasma IgA nonreactive for HIV-1, used as a negative control (triangles). The percent blocking data and the error bars shown are from two separate measurements.

Dennison, S. M., Anasti, K. M., Jaeger, F. H., Stewart, S. M., Pollara, J., Liu, P., ... & Ferrari, G. (2014). Vaccine-induced HIV-1 envelope gp120 constant region 1-specific antibodies expose a CD4-inducible epitope and block the interaction of HIV-1 gp140 with galactosylceramide. Journal of virology, 88(16), 9406-9417.